# Open-Label Study of AG10 in Patients with Cardiomyopathy

> **NCT03536767** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Eidos Therapeutics, a BridgeBio company** · enrollment: 55 (estimated)

## Conditions studied

- Amyloid Cardiomyopathy

## Interventions

- **DRUG:** AG10

## Key facts

- **NCT ID:** NCT03536767
- **Lead sponsor:** Eidos Therapeutics, a BridgeBio company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-08
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03536767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03536767, "Open-Label Study of AG10 in Patients with Cardiomyopathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03536767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*